Biotech Seeks 951% Share Dilution to Buy Illiquid Crypto Token
The treasury-trade playbook that lifted Strategy's stock for two years is cracking: dilution is no longer rewarded, and a biotech is the latest to test how far shareholders will stretch.
Biotech Seeks 951% Share Dilution to Buy Illiquid Crypto Token
🩸BEARISH
CryptoSlate
WuBlockchain